Novo Nordisk A/S (NVO)
| Market Cap | 305.65B |
| Revenue (ttm) | 43.92B |
| Net Income (ttm) | 15.16B |
| Shares Out | 4.44B |
| EPS (ttm) | 3.40 |
| PE Ratio | 20.16 |
| Forward PE | 16.97 |
| Dividend | $1.61 (2.36%) |
| Ex-Dividend Date | Mar 31, 2025 |
| Volume | 12,553,512 |
| Open | 69.45 |
| Previous Close | 67.02 |
| Day's Range | 67.65 - 70.00 |
| 52-Week Range | 57.00 - 148.15 |
| Beta | 0.21 |
| Analysts | Strong Buy |
| Price Target | 128.00 (+87.68%) |
| Earnings Date | May 7, 2025 |
About NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for NVO stock is "Strong Buy." The 12-month stock price forecast is $128.0, which is an increase of 87.68% from the latest price.
News
Novo Nordisk Woes Weigh on Denmark's Economy. Here's How.
Denmark's economy contracted 0.5% in the first quarter of 2025, largely due to the pharmaceutical industry.
If I Could Only Buy 2 Dividend Stocks Right Now (May 2025 Edition)
I've added Novo Nordisk and Novartis to boost The Dividend Income Accelerator's healthcare allocation and global diversification, reducing overall risk and volatility. Both companies are attractively ...
Final Trade: NVO, TJX, XOM & DG
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Novo Nordisk is betting on a CEO shakeup to regain its weight loss drug edge over Eli Lilly
Novo Nordisk is banking on fresh leadership to help it reclaim the crown in the booming weight loss drug market. The Danish drugmaker last week abruptly announced that longtime CEO Lars Fruergaard Jor...
Novo Nordisk announces CEO transition as share price slips
Novo Nordisk announced Friday that it would part ways with its longtime CEO, who steered the company into an unprecedented boom time for weight-loss drugs.
35 Barron's Pro-Picks: One Ideal May DiviDog
Barron's interviewed eleven financial industry Roundtable-pros who tapped 65 predictions. Six non-ADR foreign-stocks and four mutual funds were dropped by YCharts screens of active US listings, leavin...
Final Trade: MSTY, NVO, DKS, HD
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Novo Nordisk should be thinking about 'what's next,' says Dr. Kavita Patel
NBC News and MSNBC medical contributor Dr. Kavita Patel joins ‘Fast Money' to discuss Novo Nordisk after the company ousted its CEO on Friday, the competition among obesity drug makers, and more.
Novo Nordisk's CEO Ousted: Deep-Value Opportunity With Sentiment Risks
Novo Nordisk A/S' CEO exit raises governance questions, but continuity through internal succession likely limits strategic disruption. Valuation reset (~16.5x forward non-GAAP P/E) vs. LLY (~30x) crea...
Novo Nordisk should look to the US for its next CEO, analysts say
As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the Atlantic for a leader deeply entrenched in the United States, by far its largest market...
Novo Nordisk Stock: Seems Like A No-Brainer At These Levels
Novo Nordisk A/S' share price decline is driven by negative sentiment despite strong sales growth, profitability, and efficiency metrics. Competition from Eli Lilly and supply issues have pressured ma...
From insulin to Ozempic, history of Novo Nordisk's CEOs
Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the competitive obesity drug market to American rival Eli...
3 Stocks That Will Profit From Trump's Drug Price Cut
On May 12, President Donald Trump followed through on a campaign promise by signing an Executive Order (EO) mandating that pharmaceutical companies lower their prescription drug prices in the US to th...
BMO's Evan David Seigerman: Novo Nordisk CEO departure reflects disparity with Eli Lilly
Evan David Seigerman, BMO Capital Markets head of healthcare research, joins CNBC's 'Money Movers' to discuss reactions to the departure of Novo Nordisk's CEO, what is means for the company's trajecto...
Septerna: Deal With Novo Nordisk Is A Game Changer While It Still Trades Well Below Net Cash
Septerna's partnership with Novo Nordisk validates its GPCR drug discovery platform and injects $195 million in upfront cash, with potential for more than $2 billion in milestone payments. The stock t...
Ozempic maker Novo Nordisk ousts CEO amid plunging share price as rival Eli Lilly gains market share
Novo's shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes inroads into its market share and as its pipeline of new drugs has failed to...
Novo Nordisk CEO to step down, citing market challenges
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss a new leadership shakeup at drug-maker Novo Nordisk.
Novo Nordisk Boots CEO in Out-of-Character Move
It was a ‘mutual agreement,' Novo says in a statement. A search for Fruergaard Jørgensen's successor is ongoing.
SPX 6000 Close? Plus, NVO CEO Out, CAVA Dip and Buffett's STZ Position
Kevin Green joins Morning Trade Live as markets open mixed to begin Friday's trading. For the intraday S&P 500 (SPX) ranges KG is watching, he points to 5960-5970 for upward resistance.
Talks to replace Novo Nordisk CEO lasted several weeks, board chair says
Discussions between Novo Nordisk and the Novo Nordisk Foundation that controls the company regarding a CEO change have been ongoing for the past few weeks, the company's board Chair Helge Lund told Re...
Novo Nordisk CEO to step down as obesity drug competition intensifies
Novo Nordisk said on Friday that Chief Executive Officer Lars Fruergaard Jørgensen will step down, a decision made jointly with the board as the company confronts mounting competitive and financial pr...
Instant View: Wegovy-maker Novo Nordisk ousts CEO as competition in obesity drug market heats up
Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.
Novo Nordisk CEO to step down as competition weighs on Wegovy maker's share price
CNBC's Angelica Peebles joins 'Squawk Box' to report on the latest news from Novo Nordisk.
Ozempic maker Novo Nordisk boots CEO over stock-price fall
Lars Fruergaard Jorgensen, the chief executive of once-highflying Danish drugmaker Novo Nordisk, is stepping down after eight years in the role, the maker of Ozempic and Wegovy drugs announced on Frid...
Novo Nordisk CEO to Step Down Amid Market Challenges
Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to support a smooth transition to new leadership.